|Bid||8.39 x 800|
|Ask||8.40 x 3100|
|Day's Range||8.23 - 8.65|
|52 Week Range||1.80 - 9.74|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.33|
Dynavax (NASDAQ: DVAX) shares were trading 6.5% lower as of 3:35 p.m. EDT on Wednesday after competitor Pfizer (NYSE: PFE) reported data showing its vaccine produces a significantly larger number of antibodies than are found in recovered COVID-19 patients. Dynavax is collaborating with a number of companies on the development of a COVID-19 vaccine, but trials involving the adjuvant it's contributing to boost immune responses in these collaborations have only just begun, suggesting other players, including Pfizer, may reach the market sooner. On Wednesday, Pfizer and its partner, BioNTech (NASDAQ: BNTX), announced one vaccine candidate it's evaluating in a small phase 1/2 trial resulted in neutralizing antibody levels that were up to 2.8 times higher than levels seen in recovered COVID-19 patients.
Is (DVAX) Outperforming Other Medical Stocks This Year?
Dynavax Technologies Corporation (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
EMERYVILLE, Calif., June 22, 2020 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) * ADC Therapeutics SA (NYSE: ADCT) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Alpine Immune Sciences Inc (NASDAQ: ALPN)( announced a licensing agreement with AbbVie Inc (NYSE: ABBV) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Burning Rock Biotech Ltd (NASDAQ: BNR) * Castle Biosciences Inc (NASDAQ: CSTL) * Cytokinetics, Inc. (NASDAQ: CYTK) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) * Neubase Therapeutics Inc (NASDAQ: NBSE) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Protagonist Therapeutics Inc (NASDAQ: PTGX) * Royalty Pharma plc (NASDAQ: RPRX) (IPOed Monday) * Sarepta Therapeutics Inc (NASDAQ: SRPT)(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * TELA Bio Inc (NASDAQ: TELA) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * Trevena Inc (NASDAQ: TRVN) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) * CALLIDITAS THER/S ADR (NASDAQ: CALT)Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL) said the U.S. District Court for the Northern District of West Virginia ruled in its favor by invalidating Biogen Inc's (NASDAQ: BIIB) Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. Mylan noted that the patent pertains to methods of treating multiple sclerosis using a dose of 480 mg/day of dimethyl fumarate delayed release capsules, and would have disallowed generic competition until 2028.With the patent win, Mylan is allowed to launch of its dimethyl fumarate product upon the receipt of FDA approval.In pre-market trading Friday, Mylan shares were rising 2.27% to $16.70.Assembly Biosciences Regains Rights To Gastrointestinal Programs After AbbVie Terminates Deal Assembly Biosciences Inc (NASDAQ: ASMB) said it will regain worldwide rights to all microbiome gastrointestinal programs, including ABI-M201 and ABI-M301, licensed under its collaboration agreement with AbbVie's Allergan. The development follows AbbVie deciding to terminate the R&D, collaboration and license agreement. This decision was not based on any efficacy, safety, or other data related to the collaboration programs, Assembly Biosciences said.ABI-M201 is currently being evaluated in a Phase 1b trial in patients with mild to moderate ulcerative colitis and ABI-M301 is a preclinical program for Crohn's disease, the company said. The transition is expected to be completed in the fourth quarter of 2020.In pre-market trading, Assembly Biosciences shares were rising 1.95% to $22.50.Tiziana to Get Patent For Platform Technology For Oral Administration Of Fully Human Monoclonal Antibodies Tiziana Life Sciences plc (NASDAQ: TLSA) announced the United States Patent and Trademark Office has granted a patent covering its proprietary platform technology for the oral administration of Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies. The CD3 (cluster of differentiation 3) is a protein complex on T-cells, which is important for regulation of immune system, the company added. The patent will be issued by the USPTO June 23.The stock rallied 16.09% to $7 in pre-market trading.Roche Reports Positive Results For Late-Stage Prostate Cancer Study Roche Holdings AG Basel ADR (OTC: RHHBY) said the phase 3 IPATential150 study that evaluated ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care plus placebo met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumours had PTEN loss.The company said overall survival benefit and additional secondary endpoints are not yet mature and the trial will continue until the next planned analysis.Endologix CFO Departs, Announces Interim CEO Endologix, Inc. (NASDAQ: ELGX) said its CFO Vaseem Mahboob,will leave the company, effective July 1, to take over as CFO of a private global healthcare company.View more earnings on IBBThe company announced the appointment of Cindy Pinto, VP, Financial Planning & Analysis, as interim CFO in addition to her current responsibilities, and it also said it has initiated a search process for a permanent successor.Miragen Appoints Pharma Industry Veteran As COO Miragen Therapeutics Inc (NASDAQ: MGEN) announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately. Rauch, who has over 25 years of experience in the biotech and pharma industries, will report to the CEO and will be responsible for overseeing business development, licensing, partnerships, investor relations, corporate communications, intellectual property, and new product planning, the company said.In pre-market trading, the stock was up 4.20% t $1.24.Akebia Names David Spellman as CFO Akebia Therapeutics Inc (NASDAQ: AKBA) said David Spellman is joining Akebia as its new SVP, Chief Financial Officer and Treasurer, effective June 29, replacing Jason Amello, who has been serving in the position since 2013.Dynavax Says Human Trial of COVID-19 Vaccine Using Its Adjuvant Initiated Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first participants have been dosed in the Phase 1 clinical trial to evaluate Clover Biopharma's vaccine candidate to prevent COVID-19 that contains the Company's CpG 1018 adjuvant.In pre-market trading, Dynavax shares were rising 9.30% to $6.70.Earnings Urovant Sciences Ltd (NASDAQ: UROV) reported a net loss of $1.68 per share for its fiscal-year 2019 fourth quarter compared to a loss of 96 cents per share a year ago. This was wider than the consensus loss estimate of $1.24 per share.The stock was down 3.48% to $11.10 in pre-market trading.BioNano Genomics Inc's (NASDAQ: BNGO) first-quarter revenues fell from $1.8 million in 2019 to $1.1 million in 2020. The net loss widened from $7.8 million to $10.5 million.The stock was sliding 5.80% to 49 cents in pre-market trading.On The Radar PDUFA Dates Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) is knocking at the FDA altar for the second time for its investigational antibiotic contepo for treating complicated urinary tract infection. The company hinted at the decision being delayed due to the FDA requiring inspection of the facilities of third-party manufacturers in Europe.Evoke Pharma Inc (NASDAQ: EVOK) has a PDUFA date in the unfolding for its Gimoti to treat women with acute and recurrent diabetic gastroparesis.IPOs Repare Therapeutics Inc., a precision oncology company enabled by its proprietary synthetic lethality approach, priced its upsized initial public offering of 11 million shares of its common shares at $20 per share. Repare's common shares are expected to begin trading on the Nasdaq under the ticker symbol RPTX.Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, priced its IPO of 13.88 million shares at $20 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol FMTX.See more from Benzinga * The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions * The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked * The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Preclinical results demonstrated the ability of CpG 1018-adjuvanted SCB-2019 to elicit neutralizing antibodies in multiple animal speciesClover expects to enroll 150 healthy.
Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.
The trial enrolled 119 patients with end-stage renal disease undergoing hemodialysis Final immunogenicity data anticipated in Q4 2020 EMERYVILLE, Calif., June 09, 2020 --.
Shares of Dynavax (NASDAQ: DVAX) were skyrocketing 30.2% higher as of 3:47 p.m. EDT on Monday. Investors need to be cautious about putting too much focus on the comments last week made by Sinovac researcher Luo Baishan. When asked about the prospects for the COVID-19 vaccine being developed by Sinovac using Dynavax's CpG 1018 adjuvant, Baishan replied that he was 99% sure that the vaccine would be successful.
* Insider buying can be an encouraging signal for potential investors. * Beneficial owner Berkshire Hathaway made a huge purchase last week. * A director took advantage of a coronavirus vaccine contender's secondary offering.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and global economic gloom. Here are some of the most noteworthy insider purchases reported in the past week.Formula One Group Liberty Media Formula One (NASDAQ: FWONA) saw 10% owner Berkshire Hathaway Inc. (NYSE: BRK-A) add nearly 3.17 million shares of this motorsport company to its stake. At per-share prices ranging from $33.07 to $37.05, that totaled almost $112.42 million.Shares of this Liberty Media subsidiary popped more than 9% in last week's trading to end at $33.82 apiece, within the purchase price range above. The share price is up about 75% since its year-to-date low during the pandemic panic selling back in March. The analysts' consensus target price is up at $45.53.Avis Budget Beneficial owner SRS Investment Management purchased almost 500,000 Avis Budget Group Inc. (NASDAQ: CAR) shares of this New Jersey-based company last week. Share prices ranged from $18.57 to $20.59 apiece, and the total for these transactions was more than $9.88 million.Competitor Hertz Global recently filed for bankruptcy and will be delisted from the New York Stock Exchange. Avis shares ended last week up nearly 29% to $21.53, above the purchase prices mentioned above. The share price is more than 77% higher since its year-to-date low in March.See Also: What You Need To Know About Moderna's Insider SellingDynavax A Dynavax Technologies Corporation (NASDAQ: DVAX) director took advantage of a secondary offering last week. He indirectly bought a million shares for $5 apiece, which cost him $5 million. He is also a director at Mersana Therapeutics Inc (NASDAQ: MRSN) and bought more than 3 million of those shares back in April.Dynavax is among those companies in a race for a vaccine for COVID-19. Its shares soared more than 19% last week and closed most recently at $6.12 a share. It's now about 154% higher than the year-to-date low in March. The consensus price target is up at $16, though only two analysts were surveyed.In addition, note that there was some amount of insider buying at Green Dot Corporation (NYSE: GDOT), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Royal Caribbean Cruises Ltd (NYSE: RCL) last week as well.See more from Benzinga * Benzinga's Bulls And Bears Of The Week: Amazon, Disney, Netflix And More * Notable Insider Buys This Past Week: Berkshire Hathaway, Sysco And More * Barron's Picks And Pans: Dropbox, Slack, Starbucks And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Dynavax Technologies (NASDAQ: DVAX) jumped 26.4% on Friday following comments by researchers at Sinovac, a Chinese drug developer that's collaborating with Dynavax on a COVID-19 vaccine. In April, Dynavax and Sinovac agreed to collaborate to develop a vaccine for COVID-19. Dynavax is contributing an adjuvant that can boost immune responses in vaccinated patients, while Sinovac is contributing an inactivated coronavirus vaccine candidate.
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
EMERYVILLE, Calif., May 28, 2020 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares, at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, were approximately $80.5 million. Cowen, Evercore ISI and William Blair acted as joint book-running managers for the offering.
Right now, Dynavax Technologies Inc. (NASDAQ: DVAX) share price is at $5.35, after a 5.48% decrease. Over the past month, the stock went up by 57.65%, but over the past year, it actually decreased by 1.29%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.The stock is currently above from its 52 week low by 197.22%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 1.15 in the biotechnology industry, Dynavax Technologies has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Friday's Pre-Market Session * Price Over Earnings Overview: Dynavax Technologies * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, are expected to be approximately $70.0 million. In addition, Dynavax has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common stock being offered in the public offering. All of the shares in the offering will be sold by Dynavax.
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical data releases and regulatory approval decisions, which are arguably far more important metrics for gauging biotechnology firms' long-term prospects.So, how are investors supposed to distinguish between the long-term winners and those poised to take an "L"? We suggest taking a page from the analyst community's playbook.Using TipRanks' database, we were able to scan the densely populated industry for the most compelling plays. These biotech stocks not only have earned overwhelmingly bullish support from the Wall Street analysts who cover them, but sky-high upside based on the pros' estimates. Here are seven of Wall Street's best biotech stocks right now, according to the analyst community, which believes each of these picks has triple-digit return potential. SEE ALSO: Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy
Shares of the small-cap biotech Dynavax Technologies Corporation (NASDAQ: DVAX) are poised for a big day today. Investors are bidding up Dynavax's shares this morning in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today. One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July.